Immodulon Therapeutics

Immodulon Therapeutics Ltd. (London, UK) is a privately-owned, clinical-stage, immuno-oncology company primarily focused on the development of safe, effective and novel treatments for cancer. Its lead drug candidate, IMM-101, has shown promise in early clinical trials, demonstrating potential for the platform. It contains heat-killed whole cell Myc... obacterium obuense which activates dendritic cells and other cells of the innate immune system predominantly via Toll-like receptor 2. It is Immodulon's vision that IMM-101 will become a backbone immunotherapy across multiple tumour types. Its unique mechanism of action should not only make this product applicable to a range of cancers but, in combination with immune checkpoint inhibitors and any other standard-of-care treatment of the four major pillars of cancer therapy - immunotherapy, chemotherapy, radio/ablation therapy and surgery - it is also expected to increase their efficacy without compromising patient safety or quality of life.Read More